Regeneron Pharmaceuticals Inc. buy Bank of America Co.
Summary
This prediction is currently active. With a performance of 2.24%, the BUY prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc. is trending in the right direction. This prediction currently runs until 07.01.27. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | 2.24% |
| iShares Core DAX® | 2.659% |
| iShares Nasdaq 100 | 0.916% |
| iShares Nikkei 225® | 2.426% |
| iShares S&P 500 | 1.230% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
17.04.25
17.04.26
16:36
Regeneron Pharmaceuticals Inc.
12.04.24
12.04.25
13.04.25
Regeneron Pharmaceuticals Inc.
29.03.23
29.03.24
30.03.24

